Media stories about Cryolife (NYSE:CRY) have trended positive on Friday, Alpha One Sentiment Analysis reports. The research firm, a subsidiary of Accern, identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cryolife earned a news sentiment score of 0.33 on Alpha One’s scale. Alpha One also assigned media coverage about the medical equipment provider an impact score of 62 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected AlphaOne Sentiment Analysis’s analysis:
- Europe Gelatin and Bone Glue Market is projected to grow at a remarkable rate of above 6.0% by 2024 (openpr.com)
- Bioadhesives Market Progresses for Huge Profits During 2015 to 2021 (sbwire.com)
- Surgical Adhesives and Sealants Market to Develop Rapidly by 2024 (mynewsdesk.com)
- Europe Gelatin and Bone Glue Market Value is Expected to Increase to US$ 260.5 Million by 2024 (openpr.com)
- C. R. Bard, Inc. (BCR) (finance.yahoo.com)
A number of analysts recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research note on Monday, January 23rd. Northland Securities restated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research note on Friday, April 28th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Thursday, February 23rd. Finally, Ladenburg Thalmann Financial Services upgraded shares of Cryolife from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Friday, February 17th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Cryolife currently has an average rating of “Buy” and an average price target of $19.67.
Cryolife (NYSE:CRY) remained flat at $18.25 during mid-day trading on Friday. 136,750 shares of the company’s stock were exchanged. Cryolife has a one year low of $11.34 and a one year high of $20.15. The stock has a market capitalization of $607.00 million, a PE ratio of 59.25 and a beta of 1.23. The firm has a 50 day moving average of $17.03 and a 200-day moving average of $17.86.
Cryolife (NYSE:CRY) last issued its earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $45.10 million during the quarter, compared to analysts’ expectations of $44.64 million. Cryolife had a return on equity of 8.37% and a net margin of 6.00%. Cryolife’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. On average, equities research analysts expect that Cryolife will post $0.43 EPS for the current fiscal year.
In related news, VP Scott B. Capps sold 11,083 shares of the firm’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $16.40, for a total value of $181,761.20. Following the completion of the transaction, the vice president now directly owns 128,477 shares of the company’s stock, valued at $2,107,022.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.08% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Cryolife (CRY) Earns Daily Coverage Optimism Rating of 0.33” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/05/19/cryolife-cry-earns-daily-coverage-optimism-rating-of-0-33.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with MarketBeat.com's FREE daily email newsletter.